✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals
Market Cap
₹947 Cr.
P/E
11.83

Key Ratios

Market cap
Market cap
947 Cr
PE
PE
11.83
Prom Holding
Prom Holding
49.78 %
ROE (%)
ROE (%)
12.26
ROCE (%)
ROCE (%)
16.08
Div Yield (%)
Div Yield (%)
0.38
Sales
Sales
632 Cr
OPM (%)
OPM (%)
15.76 %
Debt to Equity
Debt to Equity
-

About

Lincoln Pharmaceuticals Ltd is engaged in the manufacture and marketing of affordable therapeu… Read more
Low
466
52W Range
High
872
  • Lincoln Pharma
  • Sakar Healthcare
  • Venus Remedies
  • TJI Pharma

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

7 Yes

Positive for this company

2 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0.04 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.15 %
(as of Jul 22)
Anti-Infectives - Market Share
0.80 %
(as of Nov 21)
Anti-Malarial - Market Share
0.10 %
(as of Nov 21)
Blood Related - Market Share
0.02 %
(as of Jul 22)
Cardiovascular - Market Share
0.11 %
(as of Nov 21)
Dermatology - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Lincoln Pharmaceuticals Ltd. Business

    Lincoln Pharmaceuticals Ltd specializes in producing and promoting cost-effective therapeutic products such as Tablets, Capsules, Injectables, Syrups, and Ointments.

    Lincoln Pharma major competitors are Sakar Healthcare, Venus Remedies, Bharat Parenterals, Wanbury, Fredun Pharma, Anuh Pharma, Kwality Pharma.
    Market Cap of Lincoln Pharma is ₹949 Crs.
    While the median market cap of its peers are ₹893 Crs.

    Lincoln Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material